NeueHealth Valuation
Is NEUE undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of NEUE when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NEUE's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NEUE's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NEUE?
Key metric: As NEUE is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is NEUE's PE Ratio? | |
|---|---|
| PE Ratio | 1.5x |
| Earnings | US$27.69m |
| Market Cap | US$40.77m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.1x |
| Enterprise Value/EBITDA | -12.3x |
| PEG Ratio | n/a |
Price to Earnings Ratio vs Peers
How does NEUE's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 15.9x | ||
PFHO Pacific Health Care Organization | 12.1x | n/a | US$10.5m |
PGNY Progyny | 20.8x | 19.9% | US$1.2b |
DXR Daxor | 25.9x | n/a | US$43.5m |
AMS American Shared Hospital Services | 4.9x | n/a | US$19.1m |
NEUE NeueHealth | 1.5x | n/a | US$40.8m |
Price-To-Earnings vs Peers: NEUE is good value based on its Price-To-Earnings Ratio (1.5x) compared to the peer average (15.9x).
Price to Earnings Ratio vs Industry
How does NEUE's PE Ratio compare vs other companies in the US Healthcare Industry?
| 5 Companies | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| Industry Avg. | 25.8x | 20.8% | |
NEUE NeueHealth | 1.5x | n/a | US$40.77m |
THC Tenet Healthcare | 4.6x | -39.2% | US$14.58b |
AMS American Shared Hospital Services | 4.9x | n/a | US$19.08m |
| 5 Companies | Estimated Growth | Market Cap | |
|---|---|---|---|
| Industry Avg. | 25.8x | 20.8% | |
NEUE NeueHealth | 1.5x | n/a | US$40.77m |
Price-To-Earnings vs Industry: NEUE is good value based on its Price-To-Earnings Ratio (1.5x) compared to the US Healthcare industry average (25.2x).
Price to Earnings Ratio vs Fair Ratio
What is NEUE's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 1.5x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate NEUE's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
CVS Health
US$70.2b
Provides health solutions in the United States.
CVS
US$56.83
7D
4.7%
1Y
-17.8%
Centene
US$29.2b
Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.
CNC
US$59.10
7D
1.8%
1Y
-20.4%
Elevance Health
US$91.4b
Operates as a health benefits company in the United States.
ELV
US$397.48
7D
-3.3%
1Y
-17.2%